radioprotectants

As a further vote of confidence for the new class of radioprotectants, two +$100 million BARDA contracts to develop treatments for the pulmonary/lung and hematopoietic/bone marrow sub-syndromes of acute radiation syndrome (ARS) have been awarded to companies within the past year (see Table 1).

unknown title 2011

Since the initial clinical application of radiation for the treatment of cancer, researchers have explored the use of radiation protecting compounds radioprotectants to defend normal tissues or minimize toxicity after radiation damage has occurred.

unknown title 2011

Nonetheless, despite these difficulties, several of these next-generation radioprotectants have demonstrated significant efficacy by ameliorating radiation-induced toxicities in animal studies and have been studied in Phase I clinical trials, to date without demonstrating the severe toxicities seen with Ethyol.

unknown title 2011

Nonetheless, despite these difficulties, several of these next-generation radioprotectants have demonstrated significant efficacy by ameliorating radiation-induced toxicities in animal studies and have been studied in Phase I clinical trials, to date without demonstrating the severe toxicities seen with Ethyol.

unknown title 2011

Since the initial clinical application of radiation for the treatment of cancer, researchers have explored the use of radiation protecting compounds radioprotectants to defend normal tissues or minimize toxicity after radiation damage has occurred.

unknown title 2011

Since the initial clinical application of radiation for the treatment of cancer, researchers have explored the use of radiation protecting compounds radioprotectants to defend normal tissues or minimize toxicity after radiation damage has occurred.

unknown title 2011

As a further vote of confidence for the new class of radioprotectants, two +$100 million BARDA contracts to develop treatments for the pulmonary/lung and hematopoietic/bone marrow sub-syndromes of acute radiation syndrome (ARS) have been awarded to companies within the past year (see Table 1).

unknown title 2011

By the early 1990s, Wall Street's expectations for radioprotectants were high and the market value of U.S. Bioscience exceeded $1 billion.

unknown title 2011

Products with improved safety and ease of administration could significantly expand the annual market opportunity for radioprotectants beyond $100 million and renew investor interest in the field.

unknown title 2011

By the early 1990s, Wall Street's expectations for radioprotectants were high and the market value of U.S. Bioscience exceeded $1 billion.

unknown title 2011